Skip to content
Monday, November 16, 2026
Modern Classic World

Users Discontinuing Anti-Obesity Injections Gain Back Weight at a Quadrupled Rate Compared to Dieters

Image of medical syringe and scale
Weight management involves long-term strategies.

A recent study indicates that patients who come off new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight far faster than those who stop conventional lifestyle plans.

Research printed in a leading health publication shows that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.

"Users using these drugs must be cognizant of the risk of quick rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.

This pace of recovery means a reversion to starting weight within about a year and a half.

Comparing Approaches

The study, which looked at dozens of studies involving thousands of participants, compared the effects of the injectable medications with older methods.

Researchers note that individuals who shed pounds through diet and exercise usually have a less rapid creep back—around 0.1 kg a month—post-intervention.

Explaining the Fast Rebound

Nutrition scientists believe the way of the jabs accounts for the accelerated weight return.

GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of the hormone concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.

"Discontinuation of this medication means hunger is no longer kept in check, making excessive eating much more probable."

A Chronic Condition?

Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.

A number of clinicians contend that, considering the significant potential of weight regain, the treatment is often long-term.

This view is reinforced by drug manufacturers, who state that the results "highlight the long-term character of obesity," similar to managing conditions like hypertension.

User Experiences

People who have come off the medication explain a sudden resurgence of appetite.

"It felt as if something that goes on and you're instantly ravenous," recalled an individual.

This difficulty is compounded if users have not developed permanent lifestyle or habit modifications during treatment.

Growing Use

Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.

  • Adoption is higher among women compared to men.
  • The middle-aged demographic shows the greatest level of interest.
  • A large proportion access the medications through private healthcare rather than public health services.

Ultimately, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and long-term success relies on integrated behavioural changes.

AD
About the author

Amanda Davis

Eleanor Frost is a design historian and freelance writer with a passion for timeless aesthetics and sustainable living.

Modern Classic World

Type to search articles.